BIND Therapeutics (BIND) Tops Q2 Expectations
Tweet
Share
E-mailGet Alerts BIND Hot Sheet
Join SI Premium – FREE
BIND Therapeutics (NASDAQ: BIND) reported Q2 EPS of ($0.51), $0.09 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $2.46 million versus the consensus estimate of $2.2 million.
For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Omega Flex (OFLX) Tops Q2 EPS by 27c
- Ideal Power (IPWR) Tops Q2 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
